Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name JAK1 R629_S632delinsSA
Gene Variant Detail

JAK1 R629_S632delinsSA (gain of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
JAK1 R629_S632delinsSA hematologic cancer sensitive Ruxolitinib Preclinical - Cell culture Actionable In a preclinical study, Jakafi (ruxolitinib) treatment inhibited Stat5 signaling and decreased viability of transformed cells expressing JAK1 R629_S632delinsSA in culture (PMID: 34496019). 34496019
JAK1 R629_S632delinsSA hypereosinophilic syndrome predicted - sensitive Tofacitinib Preclinical - Patient cell culture Actionable In a preclinical study, Xeljanx (tofacitinib) treatment resulted in decreased viability of blood and marrow cells derived from a patient with hypereosinophilia harboring JAK1 R629_S632delinsSA in culture (PMID: 34496019). 34496019
JAK1 R629_S632delinsSA hematologic cancer sensitive Tofacitinib Preclinical - Cell culture Actionable In a preclinical study, Xeljanz (tofacitinib) treatment resulted in decreased viability of transformed cells expressing JAK1 R629_S632delinsSA in culture (PMID: 34496019). 34496019
JAK1 R629_S632delinsSA hypereosinophilic syndrome predicted - resistant Ruxolitinib Preclinical - Patient cell culture Actionable In a preclinical study, blood and marrow cells derived from a patient with hypereosinophilia harboring JAK1 R629_S632delinsSA were resistant to Jakafi (ruxolitinib) treatment in culture (PMID: 34496019). 34496019
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries